Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...

Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting, taking ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reduced by 425,744 shares, marking a 63.01% reduction and a -0.96% impact on the ...

Pfizer and Regeneron. This press release contains forward-looking statements within the meaning of the Private Securities ...

The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...

Cash Runway: Expected to extend beyond 2027. 2seventy bio Inc (NASDAQ:TSVT) successfully completed the sale of its oncology and autoimmune R&D pipeline to Regeneron, streamlining operations. The ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, ...

We issued a press release on our third quarter, 2024 financial results. The press release can be found in the investors and media section of the company's website at 2 seventybio.com. As a reminder, ...